PharVision Advisers’s Balchem Corp BCPC Stock Holding History

PharVision Advisers’s Portfolio BCPC Stock Details BCPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,994	Closed	-$299K	–	1060
2025 Q3	$299K	Buy	+1,994	New	+$314K	0.17%	227

Other funds holding BCPC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.36B AUM 17.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PharVision Advisers's BCPC Position: Q4 2025 in Review

PharVision Advisers sold out of Balchem Corp (BCPC) in Q4 2025, closing a stake of 1,994 shares — an estimated $299K sold.

PharVision Advisers first reported a position in BCPC in Q3 2025 and held it in 1 quarter. The position peaked at $299K in Q3 2025. 409 funds tracked by Wall St. Rank hold BCPC as of Q4 2025.

PharVision Advisers reported no remaining Balchem Corp position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,994 Balchem Corp shares in Q4 2025, an estimated $299K.
PharVision Advisers first reported a position in Balchem Corp in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Balchem Corp position peaked at $299K in Q3 2025.
409 funds tracked by Wall St. Rank held Balchem Corp as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.